Sat.Feb 19, 2022 - Fri.Feb 25, 2022

article thumbnail

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

pharmaphorum

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially making it an option for a much broader group of patients. It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations.

article thumbnail

Report shines a light on unique challenges of rare disease patients

Outsourcing Pharma

In its latest diversity, equity and inclusion report, Global Genes offers insight into obstacles faced by rare-disease patients from minority communities.

105
105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Re-cap of The Year Ahead: Insights from Pharma Executives

Pharma Marketing Network

“ Being more focused, more narrow in terms of the meeting objectives, making sure the right people are there, and making sure that you have quick hit type of interventions during the course of the week to keep track of status is serving us very well. I would suggest that even if and when things return to normal, a lot of those practices and a lot of those mindsets of ways of working will probably continue even after.” – Jeff Fayer, Novartis.

article thumbnail

Ways to Access Affordable Mental Health Services

Pharma Mirror

Taking care of your mental health can be affordable. All you will have to do is choose therapy options that fit in your budget. In this article, we have outlined the most affordable therapy options. While the options fall in the lower price range, they are all capable of delivering your expected results. The post Ways to Access Affordable Mental Health Services appeared first on Pharma Mirror Magazine.

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

EU clears Bayer’s chronic kidney disease drug Kerendia

pharmaphorum

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies from AstraZeneca and Johnson & Johnson. The approval is based on the phase 3 FIDELIO-DKD trial, in which Kerendia (finerenone) reduced the risk of kidney disease progression or renal death by 18% when added to the highest tolerated dose of standard therapy.

FDA 122
article thumbnail

Genomenon forges rare-disease partnership with advocacy group

Outsourcing Pharma

The AI-centered genomics company is joining with Donât Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.

64

More Trending

article thumbnail

Abzena, Alira Health and Oncodesign launch DRIVE Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation

Pharma Mirror

Cambridge, UK, Framingham, MA (USA), and Dijon, France, Abzena, a partner research organization for integrated services from discovery through to clinical and commercial manufacturing for biologics and bioconjugates, Alira Health, an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare, and Oncodesign (ALONC -FR0011766229), a biopharmaceutical company dedicated to precision medicine, announce today that, with the launch of DRIVE™-Biologics,

52
article thumbnail

Could Facebook monitoring predict sudden epilepsy death?

pharmaphorum

A study has suggested people with epilepsy may show patterns of activity and behaviour on social media that could serve as an early warning signal for sudden death – a rare but much feared complication of the disease. The study was carried out in six individuals who suffered sudden unexpected death in epilepsy (SUDEP), with the researchers analysing hundreds of Facebook posts for each subject in the six months leading up to their death, with the consent of surviving family members.

121
121
article thumbnail

For rare disease patients, ‘every day is Rare Disease Day’

Outsourcing Pharma

On February 23, five days ahead of the day of rare-disease awareness, OSPâs Rare and Orphan Diseases webinar will share insights from top industry experts.

59
article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits: Revolutionizing the Field of Genetic Sciences

Roots Analysis

NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

V-01 as a Sequential Booster Can Produce Good Protection against Omicron Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma

Pharma Mirror

HONG KONG, Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta variants, Omicron variant emerged at the end of 2021, and its enhanced infectivity has cast a shadow over the global COVID-19 control. Recently, Omicron quickly spread in Japan and South Korea, and the number of newly confirmed cases in South Korea has exceeded 90,000 for two consecutive days.

article thumbnail

Examining COVID’s impact on clinical research participant diversity

pharmaphorum

The clinical research industry has long struggled with participant diversity. One study found that only 5% of Black or Asian United Kingdom residents had ever participated in a clinical trial. A study of FDA-approved vaccine trials from 2011-2020 showed that 78% of participants were white, even though only 60% of the U.S. population was. . And then came COVID-19.

Vaccines 111
article thumbnail

Lilly planning $700m genetic medicine development center

Outsourcing Pharma

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

52
article thumbnail

Rising Need of Autoinjectors

Roots Analysis

With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, anaphylaxis, rheumatoid arthritis and psoriasis, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Further, in order to improve the quality of life in these patients, companies have developed novel devices capable of delivering a variety of formulations of different drugs / therapies, in an efficient a

Dosage 52
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Data from first DMT-assisted clinical trial revealed

Pharma Times

No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial

66
article thumbnail

NHS gene testing missing half of people at cancer risk

pharmaphorum

A study has revealed that current NHS guidelines on testing for genetic alterations linked to cancer could be missing around half of people carrying them, says a new study. The work by scientists at the Institute for Cancer Research (ICR) suggests that access to genetic testing should be made easier because the guidelines as drawn up “would have excluded many people who had ‘actionable’ genetic alterations that could raise their risk of cancer.” Cancer is not usually inhe

105
105
article thumbnail

Viiv weighs in on FDA approval of long-acting HIV treatment

Outsourcing Pharma

A representative from the HIV-centered pharmaceutical company shares thoughts and perspective on the every-two-month treatment and how it might help patients.

article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

Roots Analysis

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. However, the conventional nucleotide library preparation process has several challenges, including requirement of huge amount of starting materials, inadequate throu

article thumbnail

MAOIs in Parkinson’s – Breakdown For Pharmacists

Med Ed 101

Pharmacists are no strangers to neurodegenerative disease. However, Parkinson’s cases present great difficulty to patients and clinicians, as our medical world lacks a solid understanding of the disease in comparison to other conditions. After Alzheimer’s disease, Parkinson’s is the second most prevalent neurodegenerative disease. It is estimated at least 1 million people in the U.S. […].

40
article thumbnail

Bia Care starts NHS trial of its digital menopause platform

pharmaphorum

A virtual menopause clinic service developed by Bia Care is starting a randomised clinical trial within the NHS that will not only test how well it performs, but also attempt to tackle inequalities in women’s health. The trial has been announced shortly after Bia Care was awarded additional funding from the NHS to extend the rollout of its digital platform, which helps women book an appointment, have a group online consultation with a doctor, get a personalised plan for managing menopause

105
105
article thumbnail

Emmes contributes data service to pediatric COVID-19 research

Outsourcing Pharma

The CRO is helping out on a project exploring the effects of the virus in children; other members of the research team include experts from Duke University.

52
article thumbnail

Nanoparticles: Emerging Stars for Pharmaceutical Industry

Roots Analysis

Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization.

article thumbnail

Free Download – 2022 Diabetes Guidelines Cheat Sheet

Med Ed 101

I recently blogged about my thoughts on the new diabetes guidelines. After that post, my friend Derek Borkowski who is the founder of Pyrls.com messaged me to offer followers of the Meded101 blog a free download. He’s put together a phenomenal resource with his 2022 Diabetes Guidelines Cheat Sheet. Simply signing up for a new […]. The post Free Download – 2022 Diabetes Guidelines Cheat Sheet appeared first on Med Ed 101.

40
article thumbnail

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The Japanese drugmaker will get access to Code Bio’s 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.

article thumbnail

FDA clears Immune-Onc to start trial of Keytruda combo in solid-tumor patients

Outsourcing Pharma

The agency has given the go-ahead for a Phase I study of the companyâs IO-202 antibody (in combination with Merckâs Keytruda) to treat various tumor types.

article thumbnail

UK health leaders call for urgent mental healthcare plan

Pharma Times

The UK government is urged to be more mindful of children and young people who have mental health issues, following the publication of the NHS Elective Recovery Plan

47
article thumbnail

MBMV invests in international bio-tech startup Arcensus GmbH

Pharma Mirror

Hoboken, NJ, Rostock/Berlin, Germany, Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion.

52
article thumbnail

How new data capabilities can supercharge clinical research

pharmaphorum

The UK’s health research data capabilities are rapidly evolving. For example, during the height of the pandemic, NIHR’s integrated health research system was able to compare COVID-19 hospital caseloads to COVID-19 research activity in real time. This enabled rapid recruitment to multiple COVID-19 clinical trials throughout England/UK. . In a post-pandemic world, how can we use insights gained from healthcare and research activity data to inform commercial research planning and placement decisio

Hospitals 105
article thumbnail

Parexel, Medidata extend decentralized clinical trial partnership

Outsourcing Pharma

The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.

52
article thumbnail

Victory Road: NHS successful in 11 year claim against Servier

Pharma Times

The European Commission finds that Servier committed a breach of competition over blood pressure drug

56
article thumbnail

MBMV invests in international bio-tech startup Arcensus GmbH

Pharma Mirror

Hoboken, NJ, Rostock/Berlin, Germany, Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion.

52
article thumbnail

To help solve patient distrust in pharma, industry collaboration is key

pharmaphorum

The past two years have shone a spotlight on the UK life sciences industry. Pharma companies are now household names, having been thrust into the public’s consciousness after dominating the headlines through the pandemic. The UK pharma sector should emerge from COVID-19 with a great deal of goodwill in the bank, especially after rapidly developing vaccines that are helping to steer the world out of the pandemic.

article thumbnail

Open Fracture Management: Antibiotics

Pharmacy Friday Pearls

Download PDF. Introduction. Open fracture wounds are considered high energy injuries that come with a high risk of infection due to the potential exposure of bone and tissue to environmental pathogens. The Gustilo- Anderson classification system grades open fractures and can be utilized to guide antimicrobial prophylaxis. For Type I fractures, which are clean wounds less than 1 centimeter long, gram positive coverage is recommended; cefazolin is usually the agent of choice.

40
article thumbnail

Greater tolerance: Allergic reactions to COVID vaccine lower for second dose

Pharma Times

Researchers discovered that recipients experiencing an allergic response to second COVID vaccine dose are minimal